during the screening period were randomised to receive either oral CEE 0.3 mg/day or an estradiol patch delivering 0.025 mg/day for 12 weeks. Patients were assessed after three 28-day cycles.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback